Financials
Financial year 2025
HG Pharma from Ottignies-Louvain-la-Neuve, company number BE0832287120, closed financial year 2025 with a result of € 144,349 after tax. For that financial year HG Pharma recorded a gross margin of € 367,522 and equity of € 427,572. Compared with financial year 2024, the result moved from € 96,520 to € 144,349. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 27, 2026.
€ 427,572
▼ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 144,349
▲ 50% vs 2024
Profit after tax over the fiscal year.
€ 30,149
▼ 60% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 190,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
0.9
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 79,135
▲ 26% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 23,569
▼ 34% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.6 million
▲ € 1.4 million vs 2024
€ 144,274 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 7,881
▲ € 7,493 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 61,061
▲ 132% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 139,743 | € 199,476 | € 227,717 | € 367,522 | ▲ 61% |
| Profit after taxes | € 123,083 | € 39,809 | € 96,520 | € 144,349 | ▲ 50% |
| Equity | € 366,894 | € 388,703 | € 473,223 | € 427,572 | ▼ 10% |
| Total debts | € 2,205,518 | € 2,191,596 | € 2,073,509 | € 4,439,571 | ▲ 114% |
| Cash | € 21,111 | € 25,428 | € 75,547 | € 30,149 | ▼ 60% |
| Retained profit | € 360,694 | € 382,503 | € 467,023 | € 421,372 | ▼ 10% |
| Dividend | € 50,000 | € 18,000 | € 12,000 | € 190,000 | ▲ € 178,000 |
| Bank debt | € 165,771 | € 201,664 | € 166,935 | € 1,590,235 | ▲ € 1.4 million |
| Balance sheet total | € 2,572,411 | € 2,580,300 | € 2,546,732 | € 4,867,143 | ▲ 91% |
| Employees (FTE) | 0.1 | 0.8 | 0.8 | 0.9 | ▲ 0.1 |
Key figures of HG Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to HG Pharma?
What happened at HG Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 144,349 (▲ 50% vs 2024). Source: NBB ↗
- New establishment in Wavre. KBO
- HELENE GEERAERTS became a director. NBB
- GILLES SMITS became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 123,083 profit in 2022 to € 144,349 profit in 2025.
Paid € 178,602 in corporate taxes since 2022.
Best year ever: 2025, with € 144,349 profit.
Paid out € 270,000 in dividends to the owners in total.
A new publication or filing at HG Pharma? We notify you, reason included.
Follow HG PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind HG Pharma are HELENE GEERAERTS and GILLES SMITS. It owns 100% of SMITS SA, 100% of PHARMACIE SMITS EUROPE and 99% of PHARMA SMITS BASSE WAVRE itself.
Directors
According to the 2025 annual accounts
since 2010
GILLES SMITS
Director
Also active at: Wavrienne de Gestion Immobilière, PHARMA PROJECT, HG IMMO, Pharmacie Smits Basse Wavre, PHARMACIE SMITS
since 2010
Establishments
Establishment units
Physical locations of this company
Avenue des Fauvettes 23
1341 Ottignies-Louvain-la-Neuve
Quai du Trompette 33 box 7
1300 Wavre
Active since 28 December 2010
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0832.287.120
- VAT number
- BE 0832.287.120
- Registered office
- Avenue des Fauvettes 23, 1341 Ottignies-Louvain-la-Neuve
- Names & denominations
- HG Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 2010
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Activiteiten van holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Holdings
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Detailhandel in farmaceutische producten
Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen
Overige financiële dienstverlening, neg